These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 25311850)
1. Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Vardakas KZ; Apiranthiti KN; Falagas ME Int J Antimicrob Agents; 2014 Dec; 44(6):486-92. PubMed ID: 25311850 [TBL] [Abstract][Full Text] [Related]
2. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. Bidell MR; Patel N; O'Donnell JN J Antimicrob Chemother; 2018 Oct; 73(10):2643-2651. PubMed ID: 30085140 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia. Rindone JP; Mellen CK Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576 [TBL] [Abstract][Full Text] [Related]
4. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711 [TBL] [Abstract][Full Text] [Related]
5. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review. Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037 [TBL] [Abstract][Full Text] [Related]
6. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Weis S; Kesselmeier M; Davis JS; Morris AM; Lee S; Scherag A; Hagel S; Pletz MW Clin Microbiol Infect; 2019 Jul; 25(7):818-827. PubMed ID: 30928559 [TBL] [Abstract][Full Text] [Related]
7. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia. Davis JS; Turnidge J; Tong S Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317 [TBL] [Abstract][Full Text] [Related]
8. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins. Li J; Echevarria KL; Traugott KA Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Shi C; Xiao Y; Zhang Q; Li Q; Wang F; Wu J; Lin N BMC Infect Dis; 2018 Oct; 18(1):508. PubMed ID: 30305037 [TBL] [Abstract][Full Text] [Related]
11. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center. Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053 [TBL] [Abstract][Full Text] [Related]
12. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia. Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065 [TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections. Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of penicillin, dicloxacillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis. Nissen JL; Skov R; Knudsen JD; Ostergaard C; Schønheyder HC; Frimodt-Møller N; Benfield T J Antimicrob Chemother; 2013 Aug; 68(8):1894-900. PubMed ID: 23599360 [TBL] [Abstract][Full Text] [Related]
15. Relative efficacy of cefuroxime versus dicloxacillin as definitive antimicrobial therapy in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-score adjusted retrospective cohort study. Rasmussen JB; Knudsen JD; Arpi M; Schønheyder HC; Benfield T; Ostergaard C J Antimicrob Chemother; 2014 Feb; 69(2):506-14. PubMed ID: 24078468 [TBL] [Abstract][Full Text] [Related]
16. Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate. Liebowitz LD; Blunt MC J Hosp Infect; 2008 Aug; 69(4):328-36. PubMed ID: 18602189 [TBL] [Abstract][Full Text] [Related]
17. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis. Lee BJ; Wang SK; Constantino-Corpuz JK; Apolinario K; Nadler B; McDanel JS; Scheetz MH; Rhodes NJ Int J Antimicrob Agents; 2019 Mar; 53(3):225-233. PubMed ID: 30476572 [TBL] [Abstract][Full Text] [Related]
18. A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study. Yaw LK; Robinson JO; Ho KM Lancet Infect Dis; 2014 Oct; 14(10):967-75. PubMed ID: 25185461 [TBL] [Abstract][Full Text] [Related]
19. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study. Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]